Every year, snakes bite as many as 5.4 million people worldwide, envenoming between 1.8 and 2.7 million of them. Around 100,000 of them die. Hundreds of thousands more are permanently disabled — losing limbs, eyesight, or kidney function. And for most of these victims, the difference between life and death comes down to a single vial of yellowish liquid that is astonishingly difficult to make and chronically in short supply. That liquid is antivenom, and its story is one of the most fascinating — and frustrating — in all of modern medicine.
A Biological Arms Race Turned Medicine
Antivenom works by exploiting the same immune system response that protects all of us from infection every day. The process begins with a horse — or sometimes a sheep — being injected with a carefully controlled, non-lethal dose of venom from the target snake species. The animal’s immune system responds by producing antibodies, specialized proteins designed to neutralize the venom’s toxic molecules.
Over several months, manufacturers repeatedly expose the animal to small doses of venom, gradually ramping up the concentration. This trains the immune system to produce large quantities of highly effective antibodies. Technicians then draw blood from the animal, extract the antibodies, and purify them into the final antivenom product.
It’s a technique that dates back to the 1890s, when French physician Albert Calmette — a colleague of Louis Pasteur — first developed a serum against cobra venom. More than 130 years later, the fundamental method hasn’t changed all that much, which is part of the problem.
The process is slow, expensive, and highly species-specific. A rattlesnake antivenom won’t work against a mamba bite. An antivenom developed for cobras in Asia may be ineffective against cobras in Africa, even within the same genus. Manufacturers must maintain living colonies of venomous snakes, extract venom safely by hand, and run clinical trials to confirm efficacy. A single finished product can take years and tens of millions of dollars to bring to market.
A Market That Leaves the Poorest Behind
Here’s where the global health crisis becomes acute. The people most at risk of snakebite are also the least profitable to serve. Subsistence farmers in sub-Saharan Africa, rural communities in South Asia, and Indigenous populations in Latin America account for the vast majority of snakebite deaths — but they have little purchasing power. Pharmaceutical companies have repeatedly entered the antivenom market and then abandoned it when profits failed to materialize.
The consequences have been devastating. In 2010, the French company Sanofi discontinued production of FAV-Afrique, one of the most effective antivenoms for West African snakebites. Remaining stockpiles ran out by 2016, creating what researchers described as a public health emergency. Replacement products were slower to arrive and, in some cases, less effective.
The World Health Organization officially classified snakebite as a “neglected tropical disease” in 2017, a designation meant to direct more research funding and attention toward conditions that disproportionately affect the poor. The WHO set a target of halving snakebite deaths and disabilities by 2030, but progress has been uneven.
In the United States, the picture is somewhat better but still imperfect. CroFab, the primary antivenom for North American pit vipers like rattlesnakes and copperheads, can cost between $2,000 and $3,000 per vial — and a serious envenomation may require 20 or more vials. That’s a potential bill exceeding $60,000 before hospital fees, a price that insurance often covers but that strains healthcare systems regardless.
The Hunt for a Better Solution
Researchers are actively working on next-generation antivenoms that could sidestep some of these limitations. One promising approach uses human monoclonal antibodies — laboratory-engineered proteins that can be designed to target specific venom toxins. These could theoretically be produced without animals, scaled up more easily, and potentially designed to work across multiple species.
Scientists at the Technical University of Denmark and the University of Washington have used AI protein design to create entirely new proteins that neutralize key neurotoxins in cobra-family venoms, protecting mice from lethal doses in a study published in Nature in 2025. Because such designed proteins are potent and stable, they could eventually offer a cheaper treatment that is easier to store and ship — a major consideration in remote regions.
Still, a universal antivenom remains a distant goal. Venoms are staggeringly complex cocktails of dozens of proteins, and what works in a lab doesn’t always work in the chaos of a real medical emergency.
For now, the best tools medicine has are the same ones Albert Calmette pioneered in the 19th century. The challenge isn’t scientific ignorance — it’s economics, logistics, and political will. Until those problems are solved, a snakebite will remain a death sentence for far too many people who simply had the misfortune of being born in the wrong part of the world.